Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 121 to 123 of 123 results for nivolumab

  1. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

    Technology appraisal guidance
    Published
    23 January 2019

  2. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    In development [GID-TA11433] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. New life-extending treatment for rare forms of advanced gastroesophageal cancer

    Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastroesophageal cancer after NICE published final draft guidance today (24 November 2022).

    News
    Last updated
    26 January 2024